An approach to antiretroviral treatment of HIV disease. Individualized therapy: the role of viral-burden measures.
Surrogate markers such as the CD4 lymphocyte count and viral p24 antigen level have now been joined by assays of HIV nucleic acid in patients' plasma as a measure of viral burden. The findings are already assisting in the development and clinical testing of antiretroviral agents. They also may facilitate therapeutic decision making for the individual patient.